Drug Profile


Alternative Names: RP 60475

Latest Information Update: 17 Jun 2002

Price : $50

At a glance

  • Originator ILEX Oncology Inc
  • Class Indoles; Pyridines; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Cancer metastases; Solid tumours

Most Recent Events

  • 17 Jun 2002 Discontinued - Phase-I for Cancer metastases in USA (IV-infusion)
  • 17 Jun 2002 Discontinued - Phase-I for Solid tumours in Canada (IV-infusion)
  • 17 Jun 2002 Discontinued - Phase-I for Solid tumours in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top